Checkpoint Therapeutics Inc (CKPT) - Total Liabilities
Based on the latest financial reports, Checkpoint Therapeutics Inc (CKPT) has total liabilities worth $17.87 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Checkpoint Therapeutics Inc net asset momentum to track the company's year-over-year net asset growth rate.
Checkpoint Therapeutics Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Checkpoint Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Checkpoint Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.
Checkpoint Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Checkpoint Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ROUTE MOBILE LIMITED
NSE:ROUTE
|
India | Rs7.35 Billion |
|
Van de Velde NV
BR:VAN
|
Belgium | €42.28 Million |
|
Regulus Resources Inc
V:REG
|
Canada | CA$1.91 Million |
|
Monro Muffler Brake Inc
NASDAQ:MNRO
|
USA | $965.03 Million |
|
Ashoka Buildcon Limited
NSE:ASHOKA
|
India | Rs64.74 Billion |
|
Hiyes International Co Ltd
TW:2348
|
Taiwan | NT$37.42 Billion |
|
Viva Wine Group AB
ST:VIVA
|
Sweden | Skr3.20 Billion |
|
Guangdong Zhengye Technology Co Ltd
SHE:300410
|
China | CN¥1.34 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Checkpoint Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Checkpoint Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Checkpoint Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Checkpoint Therapeutics Inc (2014–2024)
The table below shows the annual total liabilities of Checkpoint Therapeutics Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $20.10 Million | +9.07% |
| 2023-12-31 | $18.43 Million | -43.78% |
| 2022-12-31 | $32.77 Million | +26.14% |
| 2021-12-31 | $25.98 Million | +260.01% |
| 2020-12-31 | $7.22 Million | -11.11% |
| 2019-12-31 | $8.12 Million | -37.99% |
| 2018-12-31 | $13.09 Million | +105.48% |
| 2017-12-31 | $6.37 Million | +73.48% |
| 2016-12-31 | $3.67 Million | -13.74% |
| 2015-12-31 | $4.26 Million | -- |
| 2014-12-31 | $0.00 | -- |
About Checkpoint Therapeutics Inc
Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or m… Read more